Quizartinib and Intermediate Dose Cytarabine Consolidation Therapy. NCCP National SACT Regimen. HSE.
Regulatory approval published by the Health Service Executive.
Citation
Regulatory approvals
Approved indications from this document for cancer drugs containing at least one biomarker.
| Indication | Statements |
|---|---|
| Quizartinib in combination with cytarabine consolidation chemotherapy for adult patients with newly diagnosed acute myeloid leukaemia (AML) who are FLT3-ITD mutation positive. | 1 |
Therapeutic response
Precision oncology relationships for therapeutic response derived from this document.
| Organizations | Biomarkers | Cancer types | Therapies | |
|---|---|---|---|---|
| HSE (1) | FLT3-ITD | Acute Myeloid Leukemia | Cytarabine, Quizartinib |